Dorsomorphin treatment and inhibition on phosphorylation of adenosin monophosphate-activated protein kinaseon rats skeletal muscle
Year: 2019
Type: article
Abstract: This study has been made to determine the effect of dorsomorphin as one of the reagents on adenosine monophosphate-activated protein kinase (AMPK) inhibitor in skeletal muscle. In the experimental procedure, four and eight mg/kg-body weight/day of dorsomorphin were injected every two days for 12 consecutive days (6 times of injection) to Wistar rat. Gastrocnemius muscle immediately harvested from the Wistar rat, continued by protein expression analysis. The analysis also involved regulated mitochondrial biogenesis, including phosphorylation AMPK, SIRT, PGC-1α, VDAC and COX-IV. Results indicated that 8 mg/kg – body weight/day of dorsomorphin decreased protein expression. In the low dosage, dose, such as 4 mg/kg-body weight/day of dorsomorphin, had no impact on decreasing protein expression. Dorsomorphin decreases phosphorylation of AMPK and mitochondrial biomarker, including marker included VDAC and COX-IV on rats skeletal muscle through AMPK-SIRT-PGC-1α pathway.
Authors: Hamidie Ronald Daniel Ray, Cardial L.O. Leo-Penu, Ambar Susanti, K. Masuda
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $300
OpenAlex ID: W2977554672